Depression in Parkinson's disease: health risks, etiology, and treatment options.

Neuropsychiatric Disease and Treatment
Pasquale G FrisinaHarriet R Tenenbaum

Abstract

Depression is found in about 30%-40% of all patients with Parkinson's disease (PD), but only a small percentage (about 20%) receive treatment. As a consequence, many PD patients suffer with reduced health-related quality of life. To address quality of life in depressed PD patients, we reviewed the literature on the health correlates of depression in PD (eg, cognitive function), etiology of depression in PD, and treatment options (ie, antidepressants, electroconvulsive therapy, and psychotherapy). The current review is unique in its focus on psychosocial aspects, as well as neuropathological factors, of depression in PD. Overall, we conclude that neurochemical (eg, serotonin) and psychosocial factors (eg, coping style, self-esteem, and social support) contribute to the affective disturbances found in this neuropsychiatric population. Therefore, we recommend that a multidisciplinary (eg, pharmacotherapeutic, psychoeducational, and/or psychotherapeutic) approach to treatment be taken with depressed PD patients.

References

Feb 1, 1976·The British Journal of Psychiatry : the Journal of Mental Science·A H Robins
Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Oct 1, 1976·Journal of Neurology, Neurosurgery, and Psychiatry·M M HoehnC O Rutledge
Jan 1, 1991·Movement Disorders : Official Journal of the Movement Disorder Society·R Faber, M R Trimble
Jan 1, 1990·Journal of Geriatric Psychiatry and Neurology·T S EhmannR J Riopelle
Sep 1, 1990·Neuropsychology Review·S A RaskinJ Tweedy
Feb 1, 1987·Journal of Neurology·V S KostićB B Mrsulja
Feb 1, 1989·The British Journal of Clinical Psychology·B MacCarthy, R Brown
Jan 1, 1988·International Journal of Psychiatry in Medicine·K Y Kim, L A Hershey
Jul 1, 1987·Acta Psychiatrica Scandinavica·S C Newman, R C Bland
Apr 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·A M GothamC D Marsden
May 1, 1986·Psychological Bulletin·G A Dakof, G A Mendelsohn
Dec 1, 1973·Journal of Neurology, Neurosurgery, and Psychiatry·G G Marsh, C H Markham
Jan 1, 1974·Journal of Neurology, Neurosurgery, and Psychiatry·S Horn
Aug 1, 1967·Journal of Neurology, Neurosurgery, and Psychiatry·J W Warburton
Aug 1, 1984·Archives of General Psychiatry·F M QuitkinS O Davies
Aug 1, 1984·Neurology·C G GoetzH L Klawans
Jan 1, 1982·Progress in Brain Research·O Hornykiewicz
Nov 1, 1982·Journal of Neurology, Neurosurgery, and Psychiatry·R H MindhamC G Clough
Jun 1, 1981·Neurology·R MayeuxJ Leventhal
Jan 1, 1980·Psychological Bulletin·B E Meyerowitz
Jun 1, 1995·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·V PetoR Greenhall
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·J L MontastrucA Rascol
Mar 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·J C Dalrymple-AlfordR W Watson
Dec 1, 1993·Neurology·H EllgringW Oertel
Aug 1, 1993·Archives of Neurology·J L Cummings
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Jul 1, 1996·Journal of Neurology, Neurosurgery, and Psychiatry·A G de BoerJ C de Haes
May 1, 1997·Archives of Neurology·E TandbergJ L Cummings
Aug 1, 1997·Archives of Neurology·G KuzisS E Starkstein
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·R A Hauser, T A Zesiewicz
Apr 14, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·K H KarlsenJ G Maeland
Apr 6, 2000·The Gerontologist·L D Frazier
Jul 13, 2000·Acta Neurologica Scandinavica·B ScottS M Aquilonius
Aug 15, 2000·Neuroscience and Biobehavioral Reviews·M GesiF Fornai
Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S TeseiG Pezzoli
Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A F LeentjensJ Troost
Feb 24, 2001·Psychological Medicine·A SchragN P Quinn

❮ Previous
Next ❯

Citations

Jul 27, 2010·Journal of Gerontological Social Work·Zvi D Gellis
Oct 5, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F Stocchi, B R Bloem
Feb 26, 2010·Cases Journal·Magda TsolakiAthanasios Karatolias
Feb 10, 2017·Nanomedicine·Shuguftha NazSantimukul Santra
Apr 15, 2017·Neurology. Clinical Practice·Zahra Goodarzi, Zahinoor Ismail
Dec 31, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Gretchen O ReynoldsAlice Cronin-Golomb
Oct 15, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Nancy A PachanaSergio Starkstein

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

Psych
Info

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Stacey McCoy, Kathleen Baldwin
Neurosciences : the Official Journal of the Pan Arab Union of Neurological Sciences
Medhat M Bassiony
© 2022 Meta ULC. All rights reserved